RIL
DSGN icon

Rothschild Investment LLC’s Design Therapeutics DSGN Stock Holding History

Rothschild Investment LLC’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$318 Sell
22
-1
-4% -$12 ﹤0.01% 3356
2026
Q1 		$245 Buy
+23
New +$233 ﹤0.01% 3271

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Rothschild Investment LLC's DSGN Position: Q2 2026 in Review

Rothschild Investment LLC reduced its Design Therapeutics (DSGN) stake by 4.3% in Q2 2026, selling an estimated $12 and leaving 22 shares worth $318. The position accounts for ﹤0.01% of the portfolio, ranked #3356.

Rothschild Investment LLC first reported a position in DSGN in Q1 2026 and has held it in 2 quarters since. 136 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • Rothschild Investment LLC held 22 shares of Design Therapeutics worth $318 as of Q2 2026.
  • Rothschild Investment LLC sold 1 Design Therapeutics share in Q2 2026, an estimated $12.
  • Design Therapeutics made up ﹤0.01% of Rothschild Investment LLC's portfolio in Q2 2026, its #3356 holding.
  • Rothschild Investment LLC first reported a position in Design Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 136 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Rothschild Investment LLC's 13F filing for Q2 2026, filed 6 Aug 2026.